Subscribe to Dr. Mirkin's free FITNESS & HEALTH NEWSLETTER

A study in the New England Journal of Medicine shows that a class of drugs to block estrogen is highly successful in preventing recurrence of breast cancer. Women who have had breast cancer are always at risk for recurrence. The female hormone, estrogen, has to attach to breast cells on special hooks called estrogen receptors, before it can stimulate breast cells to grow. Doctors routinely prescribe the drug, Tamoxifen, to attach to these receptors to prevent estrogen from attaching to them and stimulating breast cancer cells to grow. However, after five years, Tamoxifen often stops doing its job.

The authors of this study gave these women, who had had Tamoxifen, a new drug called Femara, made by Novartis, and it halved the risk of breast cancer returning. The results were so dramatic, that the doctors felt morally responsible to stop the study and offer Femara to all the women in the study. Doctors still do not know how long to prescribe Femara or its long-term toxic effects. Femara, also known as letrozole suppresses production of estrogen. Side effects include osteoporosis, hot flashes, night sweats and bone pain.

New England Journal of Medicine , November 6, 2003

Checked 9/3/05

May 12th, 2013
|   Share this Report!

About the Author: Gabe Mirkin, MD

Sports medicine doctor, fitness guru and long-time radio host Gabe Mirkin, M.D., brings you news and tips for your healthful lifestyle. A practicing physician for more than 50 years and a radio talk show host for 25 years, Dr. Mirkin is a graduate of Harvard University and Baylor University College of Medicine. He is board-certified in four specialties: Sports Medicine, Allergy and Immunology, Pediatrics and Pediatric Immunology. The Dr. Mirkin Show, his call-in show on fitness and health, was syndicated in more than 120 cities. Read More
Subscribe to Dr. Mirkin's free FITNESS & HEALTH NEWSLETTER
Copyright 2019 Drmirkin | All Rights Reserved | Powered by Xindesigns